Catalyst Pharmaceuticals, Inc. (CPRX)
NASDAQ: CPRX · Real-Time Price · USD
23.23
-0.16 (-0.68%)
At close: Mar 13, 2026, 4:00 PM EDT
23.71
+0.48 (2.07%)
After-hours: Mar 13, 2026, 7:45 PM EDT
Catalyst Pharmaceuticals Stock Forecast
Stock Price Forecast
The 1 analyst with a 12-month price forecast for Catalyst Pharmaceuticals stock has a target of 35, which predicts a 50.67% increase from the current stock price of 23.23.
Price Target: $35 (+50.67%)
Analyst Consensus: Strong Buy
Analyst Ratings
According to 1 stock analyst, the rating for Catalyst Pharmaceuticals is "Strong Buy". This means that the analyst believes this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 1 |
| Buy | 4 | 2 | 2 | 2 | 2 | 0 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 6 | 6 | 6 | 6 | 1 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Citigroup | Citigroup | Strong Buy Maintains $33 → $35 | Strong Buy | Maintains | $33 → $35 | +50.67% | Mar 3, 2026 |
| Citigroup | Citigroup | Strong Buy Maintains $31 → $33 | Strong Buy | Maintains | $31 → $33 | +42.06% | Nov 7, 2025 |
| Baird | Baird | Buy Maintains $28 → $32 | Buy | Maintains | $28 → $32 | +37.75% | Mar 3, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $35 | Strong Buy | Reiterates | $35 | +50.67% | Feb 28, 2025 |
| Stephens & Co. | Stephens & Co. | Buy Reiterates $33 | Buy | Reiterates | $33 | +42.06% | Feb 27, 2025 |
Financial Forecast
Revenue This Year
636.12M
from 588.99M
Increased by 8.00%
Revenue Next Year
698.28M
from 636.12M
Increased by 9.77%
EPS This Year
1.93
from 1.68
Increased by 14.99%
EPS Next Year
2.16
from 1.93
Increased by 11.83%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 671.7M | 764.3M | |||
| Avg | 636.1M | 698.3M | |||
| Low | 589.6M | 627.9M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 14.0% | 20.2% | |||
| Avg | 8.0% | 9.8% | |||
| Low | 0.1% | -1.3% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 2.14 | 2.75 | |||
| Avg | 1.93 | 2.16 | |||
| Low | 1.71 | 1.71 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 27.5% | 42.4% | |||
| Avg | 15.0% | 11.8% | |||
| Low | 1.5% | -11.7% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.